Search Results - "immunogenicity"

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study by Remon Abu-Elyazeed, William Jennings, Randall Severance, Michael Noss, Adrian Caplanusi, Michael Povey, Ouzama Henry

Connect to this object online.

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life by Tessa Hosman, Roy van Heesbeen, Arangassery Rosemary Bastian, Weihong Hu, Christy Comeaux, Nynke Ligtenberg, Bart van Montfort, Benoît Callendret, Esther Heijnen

Connect to this object online.

26 Towards an HIV functional cure with CAR-T cells: elucidating mechanisms underlying the extremely high potency of bispecific anti-HIV CARs designed for optimal activity and minimal immunogenicity by M.H. Ghanem, B. Dey, S. Bolivar-Wagers, D. Vargas-Inchaustegui, V. Bundoc, D.T. Danielson, D. Elias, A. Hajduczki, E.A. Berger

Connect to this object online.

Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty by Suvimol Niyomnaitham, Kulkanya Chokephaibulkit, Chatkamol Pheerapanyawaranun, Zheng Quan Toh, Paul V. Licciardi, Arpa Satayasanskul, Laddawan Jansarikit, Prasert Assantachai

Connect to this object online.

A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age by Kai Chu, Yuemei Hu, Hongxing Pan, Jingliang Wu, Dandan Zhu, Mariano M. Young, Li Luo, Zhuobiao Yi, Peter C. Giardina, William C. Gruber, Daniel A. Scott, Wendy Watson

Connect to this object online.

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyResearch in context by Prasad S. Kulkarni, Abhijit Kadam, Sheela Godbole, Varsha Bhatt, Abhishek Raut, Sunil Kohli, Santanu Tripathi, Praveen Kulkarni, Rakhi Ludam, Madhav Prabhu, Ashish Bavdekar, Nithya J. Gogtay, Sushant Meshram, Tamilarasu Kadhiravan, Sonali Kar, D.H. Ashwath Narayana, Clarence Samuel, Govind Kulkarni, Abhay Gaidhane, Dipu Sathyapalan, Sidram Raut, Vijay Hadda, Hira Lal Bhalla, Chetanraj Bhamare, Abhijeet Dharmadhikari, Joyce S. Plested, Shane Cloney-Clarke, Mingzhu Zhu, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ashwini Shete, Manish Gautam, Nivedita Gupta, Samiran Panda, Umesh Shaligram, Cyrus S. Poonawalla, Balram Bhargava, Bhagwat Gunale, Dhananjay Kapse, Shubhangi A. Kanitkar, Arjun L. Kakrani, Srikanth P. Tripathy, Abhijit V. Tilak, Akshay A. Dhamne, Shahzad Beg Mirza, Prachi V. Athavale, Mandakini Bhowmik, Parag J. Ratnakar, Subodh Gupta, Vijayshri Deotale, Jyoti Jain, Ashwini Kalantri, Vineet Jain, Nidhi Goyal, Alok Arya, Temsunaro Rongsen-Chandola, Shreyasi Dasgupta, Pratibha Periera, Vanmathi A, Anand Kawade, Arunkumar Gondhali, Palvi Kudyar, Abhishek Singh, Ravi Yadav, Alina Alexander, Venugopalan Gunasekaran, Sekar Dineshbabu, P.C. Samantaray, H.S. Ravish, Deepshikha Kamra, Shilpa Gaidhane, Quazi Syed Zahiruddin, Merlin Moni, Anil Kumar, Ameet Dravid, Anant Mohan, Tejas Suri, Tejas K. Patel, Surekha Kishore, Rahul Choche, Deepak Ghatage, Sugam Salvi

Connect to this object online.

The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death by Xiao-Chuan Duan, Li-Yuan Peng, Xin Yao, Mei-Qi Xu, Hui Li, Shuai-Qiang Zhang, Zhuo-Yue Li, Jing-Ru Wang, Zhen-Han Feng, Guang-Xue Wang, Ai Liao, Ying Chen, Xuan Zhang

Connect to this object online.

Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial by Dandan Zhu, Yuansheng Hu, Zhiwei Jiang, Tuantuan Yang, Kai Chu, Hengming Zhang, Jialei Hu, Xing Meng, Zhijun Tan, Jingliang Wu, Xiaojuan Lian, Changgui Li, Hongxing Pan

Connect to this object online.

A randomized, open-label clinical trial to evaluate immunogenicity and safety of an indigenously developed DTwP-Hib tetravalent combination vaccine (Easyfour®-TT) with Quadrovax® in Indian infants by Lalitendu Mohanty, Sunil Sharma, Beauty Behera, Sachin Panwar, Charu Paliwal, Anit Singh, Anu Gupta, Deepak Chandra Chilkoti

Connect to this object online.

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults by Isabel Leroux-Roels, Geert Leroux-Roels, Georgi Shukarev, Hanneke Schuitemaker, Conor Cahill, Richard de Rooij, Martin Struijs, Hester van Zeeburg, Jeanne-Marie Jacquet

Connect to this object online.

Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts by Sorawit Chittrakarn, Pisud Siripaitoon, Sarunyou Chusri, Siripen Kanchanasuwan, Boonsri Charoenmak, Thanaporn Hortiwakul, Phaiwon Kantikit, Narongdet Kositpantawong

Connect to this object online.

A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults by Antonios O. Aliprantis, Christine A. Shaw, Paul Griffin, Nicholas Farinola, Radha A. Railkar, Xin Cao, Wen Liu, Jeffrey R. Sachs, Christine J. Swenson, Heather Lee, Kara S. Cox, Daniel S. Spellman, Colleen J. Winstead, Igor Smolenov, Eseng Lai, Tal Zaks, Amy S. Espeseth, Lori Panther

Connect to this object online.

Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials by Ngoc Huu Tran, Danaya Chansinghakul, Chia Yin Chong, Chian Yong Low, Lynette P. Shek, Chan Quang Luong, Carina Frago, T. Anh Wartel, Sunny Sun, Anna Skipetrova, Alain Bouckenooghe

Connect to this object online.

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population by Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Bothamai Dechates, Harnphadungkit Monprach, Gaidganok Sornsamdang, Kasiruck Wittayasak, Kamonwan Soonklang, Nithi Mahanonda

Connect to this object online.

Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study by Ki Hwan Kim, Chun Soo Kim, Hwang Min Kim, Jong-Duck Kim, Sang Hyuk Ma, Dong Ho Kim, Pyoung-Han Hwang, Ji-Whan Han, Taek-Jin Lee, Joon Hyung Kim, Naveen Karkada, Narcisa Mesaros, Woo-Yun Sohn, Jong-Hyun Kim

Connect to this object online.

Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study by Germán Áñez, James Hedrick, Michael W. Simon, Shane Christensen, Robert Jeanfreau, Eddy Yau, Judy Pan, Emilia Jordanov, Mandeep S. Dhingra

Connect to this object online.

Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden by Sofia Sagredou, Panagiotis Dalezis, Eirini Papadopoulou, Maria Voura, Maria V. Deligiorgi, Michail Nikolaou, Mihalis I. Panayiotidis, George Nasioulas, Vasiliki Sarli, Dimitrios T. Trafalis

Connect to this object online.

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents by Pio Lopez, Lulu Bravo, Erik Buntinx, Charissa Borja-Tabora, Hector Velasquez, Edith Johana Rodriquez, Camilo A. Rodriguez, Josefina Carlos, May Emmeline B. Montellano, Edison R. Alberto, Milagros Salvani-Bautista, Yung Huang, Branda Hu, Ping Li, Htay Htay Han, Carmen Baccarini, Igor Smolenov

Connect to this object online.

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study by Judith Kirstein, Miriam Pina, Judy Pan, Emilia Jordanov, Mandeep S. Dhingra

Connect to this object online.

A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. by Anna P Durbin, Stephen S Whitehead, Donna Shaffer, Dan Elwood, Kimberli Wanionek, Bhavin Thumar, Joseph E Blaney, Brian R Murphy, Alexander C Schmidt

Connect to this object online.